摘要上世纪50年代,减肥手术开始用于治疗肥胖症,最初的临床观察发现,肥胖患者术后不仅体重显著下降,而且其并发的非胰岛素依赖型糖尿病得到意想不到的治愈或改善。但这一现象并未引起关注,至1998年,East Carolina大学Brody医学院的Pories等在Annals of Surgery杂志报道了减肥手术后的随访研究结果,才引起了学术界的高度重视。
4Patriti A,Facchiano E,Sanna A,et al.The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery[J].Obes Surg,2004,14(6):840-841.
5DRUCKER DJ.Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes[J].Diabetes Care,2007,30(6):1335-1343.
2DRUCKER DJ. Dipeptidyl peptidase4 inhibition and the treatment of type 2 diabetes[J]. Diabetes Care, 2007, 30 (6): 1335 - 1343.
3THOMA R, LOFFLER B, STIHLE M, et al. Structural basis of proline-specific exopeptidase activity as observed in human dipepfidyl peptidase-IV[J]. Structure, 2003, 11(8): 947 -959.
4AHREN B. Inhibition of Dipeptidyl peptidase-d-(dpp-4) - a novel approach to treat type 2 diabetes[ J]. Current Enzyme Inhibition, 2005, 1 (1) : 65 -73.
5HARTEL S, GOSSRAU R, HANSKI C,et al. Dipeptidyl peptidase (DPP) Ⅳ in rat organs : comparison of immunohistochemistry and activity histochemistry [ J ]. Histochemlstry, 1988, 89 (2) : 151 - 161.
6FLEISCHER B. CD26 : a surface protease involved in T-cell activation[J], lmmunol Today, 1994, 15(4): 180-184.
7IKEHARA Y, OGATA S, MISUMI Y. Dipeptidyl-peptidase Ⅳ from rat liver[J]. Method Enzymol, 1994, 244:2215 -2227.
8MENTLEIN R. Dipeptidyl peptidase IV(CD26) role in the inactivation of regulatory peptides [ J ]. Regul Pept, 1999, 85 ( 1 ) : 9 - 24.
9ASAKURA KJ, TOMITA KY, UEDA TC, et al. Novel long-acting incretin mimetics glycosylated glucagons-like peptide 1 exert improved dipeptidyl peptidase IV resistance and potent anti-dia- betic Efficacy[ C ]. American Diabetes Association-68th Scientific Sessions 6-10. Sanfrancisco, California,USA. 2008.
10POSPISILIK JA, MARTIN J, DOTY T, et al. Dipeptidyl peptidase Ⅳ inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats [ J ]. Diabetes, 2003, 52(3) :741 -750.
5Pofies WJ,Swanson MS,MacDonald KG,et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset di- abetes meUitus. Ann Surg,1995,222:339-350.
6Brolin RE. Bariatric surgery and long-term control of morbid obesity. JAMA,2002,288:2793-2796.
7Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non- obese animal model of type 2 diabetes : a new perspective for an old disease. Ann Surg,2010,239 : 1-11.
8Ramos AC, Galvao Neto MP, de Souza YM, et al. Laparoscopic duode- nal-jejunal exclusion in the treatment of type 2 diabetes mellitus in pa- tients with BMI < 30 kg/m^2 ( LBMI). Obes Surg.2009.19:307-312.
9Degn KB ,Juhl CB, Sturis J, et al. One weekg treatment with the long- acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes ,2010,53 : 1187-1194.
10Buchwald H, A vidor Y, Braunwald E, et al. Bariatric surgery: a system atie review and meta- analysis[J]. JAMA, 2004,292 (14):1724-1737.
